Novadoz Pharmaceuticals Initiates Nationwide Recall of Glycopyrrolate Oral Solution Due to Impurity Failures
Novadoz Pharmaceuticals LLC has initiated a nationwide Class III recall for specific lots of Glycopyrrolate Oral Solution. This action, stemming from failed impurity and degradation specifications, impacts the US pharmaceutical supply chain. Procurement directors and regulatory affairs heads must assess inventory and supplier quality to mitigate disruption and ensure compliance amidst ongoing FDA scrutiny.
FDA Action on Glycopyrrolate Oral Solution Impurity Failure
Novadoz Pharmaceuticals LLC has initiated a voluntary Class III recall, designated D-0300-2026, for specific lots of its Glycopyrrolate Oral Solution, 1 mg/5 mL, 16 oz. (473 mL), Rx only. The primary reason for this nationwide recall is the product's failure to meet established impurity and degradation specifications. This critical quality issue affects product with NDC 72205-070-72, specifically lot numbers CB2505159A and CB2505160A, both with an expiration date of April 2027, and lot number CB2505161A, expiring in May 2027. The FDA's Class III classification indicates that while the use of or exposure to the violative product is not likely to cause adverse health consequences, its removal from the market is necessary. For procurement directors, this event necessitates an immediate assessment of existing inventory of Novadoz-distributed Glycopyrrolate Oral Solution, particularly the identified lots. Regulatory affairs heads must review their internal quality control and supplier qualification protocols to prevent sourcing products with similar impurity profiles. Supply chain VPs should anticipate potential short-term supply disruptions for this specific formulation across the U.S. market and initiate contingency planning. The presence of degradation products, even at a low-risk classification, signals a potential breach in Good Manufacturing Practices (GMP) that requires thorough investigation and remediation by the manufacturer, MSN Pharmaceuticals Inc., and diligent oversight by the distributor, Novadoz. This incident underscores the critical importance of robust stability testing and adherence to product specifications throughout a drug's entire shelf life.
Manufacturing and Distribution Footprint of Recalled Glycopyrrolate Product
The recalled Glycopyrrolate Oral Solution was manufactured by MSN Pharmaceuticals Inc. in Piscataway, NJ 08854, and subsequently distributed by Novadoz Pharmaceuticals LLC from its facility at 20 Duke Rd Ste A, Piscataway, NJ 08854-3714. This product, identified by ANDA216084, is an anticholinergic medication used for various therapeutic applications. The distribution pattern for this specific recall is explicitly stated as "US Nationwide," indicating a broad market reach for the affected product. For procurement and supply chain leaders, this dual-entity involvement—with MSN Pharmaceuticals as the manufacturer and Novadoz Pharmaceuticals as the distributor—necessitates a clear understanding of accountability and quality agreements within their supply networks. While Novadoz initiated the voluntary recall, the manufacturing quality issue, specifically the failed impurity and degradation specifications, originates with MSN Pharmaceuticals. Companies sourcing Glycopyrrolate, particularly the oral solution formulation, must verify their supplier relationships, confirming whether they procure directly from MSN or through distributors like Novadoz. The nationwide distribution pattern means that any healthcare provider, pharmacy, or wholesaler in the United States could be affected, requiring extensive communication and logistical coordination for product retrieval. Business development executives should note that this recall could create opportunities for alternative manufacturers or distributors of Glycopyrrolate to capture market share, provided they can demonstrate superior quality and supply chain reliability.
Commercial and Regulatory Implications for the US Market
The "Ongoing" status of this voluntary, firm-initiated recall (D-0300-2026) means that continued vigilance and proactive measures are required from all stakeholders in the pharmaceutical supply chain. Although the Class III classification indicates a low probability of adverse health consequences, it still mandates the effective removal of the non-compliant product from the market to maintain public trust and regulatory standards. Regulatory affairs teams must monitor the FDA's oversight of Novadoz Pharmaceuticals LLC and MSN Pharmaceuticals Inc.'s corrective actions. While this is a firm-initiated recall, the FDA's classification and monitoring underscore the agency's expectation for prompt and effective resolution of quality deviations. Procurement professionals should proactively engage with their current Glycopyrrolate suppliers to confirm their product's compliance with impurity specifications and stability data, irrespective of whether they source from Novadoz or MSN. The broader regulatory landscape, as evidenced by recent FDA Class II recalls involving other firms such as Essential Wellness Pharma's Progesterone Injection and Spectra Medical Devices' Lidocaine HCl Injection, signals an unwavering focus on pharmaceutical quality and patient safety. This persistent scrutiny means that companies must continuously fortify their quality management systems to mitigate recall risks, protect brand reputation, and ensure uninterrupted supply to patients across the US. Business development teams might explore strategic partnerships or acquisitions that enhance quality control capabilities or diversify supply sources for critical medications like Glycopyrrolate.